PAS
MGX icon

Point72 Asia (Singapore)’s Metagenomi Therapeutics MGX Stock Holding History

Point72 Asia (Singapore)’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$11.7K Sell
4,922
-5,388
-52% -$10.9K ﹤0.01% 767
2025
Q2 		$15.3K Buy
+10,310
New +$16.1K ﹤0.01% 765
2024
Q4 		– Sell
-7,415
Closed -$16.1K – 1269
2024
Q3 		$16.1K Buy
+7,415
New +$25.7K ﹤0.01% 837

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Point72 Asia (Singapore)'s MGX Position: Q3 2025 in Review

Point72 Asia (Singapore) reduced its Metagenomi Therapeutics (MGX) stake by 52% in Q3 2025, selling an estimated $10.9K and leaving 4,922 shares worth $11.7K. The position accounts for ﹤0.01% of the portfolio, ranked #767.

Point72 Asia (Singapore) first reported a position in MGX in Q3 2024 and has held it in 3 quarters since. The position peaked at $16.1K in Q3 2024. 58 funds tracked by Wall St. Rank hold MGX as of Q3 2025.

  • Point72 Asia (Singapore) held 4,922 shares of Metagenomi Therapeutics worth $11.7K as of Q3 2025.
  • Point72 Asia (Singapore) sold 5,388 Metagenomi Therapeutics shares in Q3 2025, an estimated $10.9K.
  • Metagenomi Therapeutics made up ﹤0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #767 holding.
  • Point72 Asia (Singapore) first reported a position in Metagenomi Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Point72 Asia (Singapore)'s Metagenomi Therapeutics position peaked at $16.1K in Q3 2024.
  • 58 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.